engages in the development and marketing of synthetic-based biomaterial products for use in spine surgery, the repair of osteoporotic fractures, and a range of clinical needs in the trauma, joint reconstruction, revision, and extremities markets primarily in the United States.
Its products include VITOSS bone graft substitute (VITOSS), IMBIBE bone marrow aspirate syringe (IMBIBE), ENDOSKELETON TA device, CORTOSS synthetic cortical bone void filler (CORTOSS), VITAGEL surgical hemostat, and ALIQUOT microdelivery system.
VITOSS is an ultra-porous resorbable beta-tricalcium phosphate bone void filler used to enable the body guide the three-dimensional regeneration of the patient’s own bone.
The IMBIBE provides spine and orthopedic surgeons with a method for harvesting a patient’s bone marrow, mixing it with VITOSS and delivering the mixture to the bone graft site.
ENDOSKELETON TA device provides physiological support to, or replaces damaged vertebral bodies.
The CORTOSS is a bone-bonding and self-setting composite engineered specifically to mimic the characteristics of human cortical bone.
VITAGEL is a composite liquid hemostat that combines the biomaterials thrombin and collagen with the patient’s autologous plasma for soft-tissue healing.
The ALIQUOT microdelivery system facilitates delivery of the company’s CORTOSS product directly to the surgical site.
Orthovita also offers VITOMATRIX particulate synthetic scaffold biomaterial and bone graft substitute materials, such as VITOSS FOAM products, which combine VITOSS technology with resorbable biomaterials to produce an array of pliant, flexible, flowable, and compression resistant bone graft materials.
In addition, the company distributes products, which compliment its biomaterial platforms.
It sells its products through direct sales force, independent sales agency, and stocking distributors.
Orthovita was incorporated in 1992 and is headquartered in Malvern, Pennsylvania.
